Searched for: person:cifuea01
in-biosketch:true
Antibody Titers against Mpox Virus after Vaccination [Letter]
Kottkamp, Angelica C; Samanovic, Marie I; Duerr, Ralf; Oom, Aaron L; Belli, Hayley M; Zucker, Jane R; Rosen, Jennifer B; Mulligan, Mark J; ,
PMID: 38091537
ISSN: 1533-4406
CID: 5589312
Heterologous SARS-CoV-2 Booster Vaccinations - Preliminary Report
Atmar, Robert L; Lyke, Kirsten E; Deming, Meagan E; Jackson, Lisa A; Branche, Angela R; El Sahly, Hana M; Rostad, Christina A; Martin, Judith M; Johnston, Christine; Rupp, Richard E; Mulligan, Mark J; Brady, Rebecca C; Frenck, Robert W; Bäcker, MartÃn; Kottkamp, Angelica C; Babu, Tara M; Rajakumar, Kumaravel; Edupuganti, Srilatha; Dobryzynski, David; Posavad, Christine M; Archer, Janet I; Crandon, Sonja; Nayak, Seema U; Szydlo, Daniel; Zemanek, Jillian; Islas, Clara P Dominguez; Brown, Elizabeth R; Suthar, Mehul S; McElrath, M Juliana; McDermott, Adrian B; O'Connell, Sarah E; Montefiori, David C; Eaton, Amanda; Neuzil, Kathleen M; Stephens, David S; Roberts, Paul C; Beigel, John H
Background/UNASSIGNED:While Coronavirus disease 2019 (Covid-19) vaccines are highly effective, breakthrough infections are occurring. Booster vaccinations have recently received emergency use authorization (EUA) for certain populations but are restricted to homologous mRNA vaccines. We evaluated homologous and heterologous booster vaccination in persons who had received an EUA Covid-19 vaccine regimen. Methods/UNASSIGNED:virus particles, or Pfizer-BioNTech BNT162b2 30-μg; nine combinations). The primary outcomes were safety, reactogenicity, and humoral immunogenicity on study days 15 and 29. Results/UNASSIGNED:458 individuals were enrolled: 154 received mRNA-1273, 150 received Ad26.CoV2.S, and 153 received BNT162b2 booster vaccines. Reactogenicity was similar to that reported for the primary series. Injection site pain, malaise, headache, and myalgia occurred in more than half the participants. Booster vaccines increased the neutralizing activity against a D614G pseudovirus (4.2-76-fold) and binding antibody titers (4.6-56-fold) for all combinations; homologous boost increased neutralizing antibody titers 4.2-20-fold whereas heterologous boost increased titers 6.2-76-fold. Day 15 neutralizing and binding antibody titers varied by 28.7-fold and 20.9-fold, respectively, across the nine prime-boost combinations. Conclusion/UNASSIGNED:Homologous and heterologous booster vaccinations were well-tolerated and immunogenic in adults who completed a primary Covid-19 vaccine regimen at least 12 weeks earlier. (Funded by National Institute of Allergy and Infectious Diseases; Clinical Trials.gov number, NCT04889209 ).
PMCID:8528081
PMID: 34671773
ISSN: n/a
CID: 5086922
Prevalence of Strongyloidiasis Among Cardiothoracic Organ Transplant Candidates in a Non-Endemic Region; A Single Center Experience with Universal Screening
Kottkamp, Angelica C; Filardo, Thomas D; Holzman, Robert S; Aguero-Rosenfield, Maria; Neumann, Henry J; Mehta, Sapna A
Disseminated strongyloidiasis and hyperinfection syndrome can cause significant morbidity and mortality after transplantation. Screening and treatment prior to transplantation can reduce or prevent this disease. Targeted screening of transplant candidates, based on assessed risk, fails to identify all who would benefit. We implemented universal serology-based screening for Strongyloides at our transplant center, located in a non-endemic area. Of 200 transplant candidates who were evaluated for cardiothoracic transplant from January 2018 to June 2019, 169 were screened serologically and 21 (12.4%) were seropositive. Among seropositive patients, 57% reported travel to an endemic region, 38% were born outside the USA, 38% had eosinophilia, 5% had history of gram-negative bacteremia. We estimate that universal screening for strongyloidiasis could identify an average of 17 additional candidates for preventive treatment for every 200 transplant candidates.
PMID: 33844416
ISSN: 1399-3062
CID: 4841002
The LGBTQ+ communities and the COVID-19 pandemic: a call to break the cycle of structural barriers
Gil, Raul Macias; Freeman, Tracey; Mathew, Trini; Kullar, Ravina; Ovalle, Anais; Nguyen, Don; Kottkamp, Angélica; Poon, Jin; Marcelin, Jasmine; Swartz, Talia H
The COVID-19 pandemic has disproportionately impacted LGBTQ+ communities. Many disparities mirror those of the HIV/AIDS epidemic. These health inequities have repeated throughout history due to the structural oppression of LGBTQ+ people. We aim to demonstrate that the familiar patterns of LGBTQ+ health disparities reflect a perpetuating, deeply rooted cycle of injustice imposed on LGBTQ+ people. Here, we contextualize COVID-19 inequities through the history of the HIV/AIDS crisis, describe manifestations of LGBTQ+ structural oppression exacerbated by the pandemic, and provide recommendations for medical professionals and institutions seeking to reduce health inequities.
PMID: 34323998
ISSN: 1537-6613
CID: 4969032
Mucosal and Systemic Antibody Responses After Boosting With a Bivalent Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine
Atmar, Robert L; Lyke, Kirsten E; Posavad, Christine M; Deming, Meagan E; Brady, Rebecca C; Dobrzynski, David; Edupuganti, Srilatha; Mulligan, Mark J; Rupp, Richard E; Rostad, Christina A; Jackson, Lisa A; Martin, Judith M; Shriver, Mallory C; Rajakumar, Kumaravel; Coler, Rhea N; El Sahly, Hana M; Kottkamp, Angelica C; Branche, Angela R; Frenck, Robert W; Johnston, Christine; Babu, Tara M; Bäcker, Martín; Archer, Janet I; Crandon, Sonja; Nakamura, Aya; Nayak, Seema U; Szydlo, Daniel; Dominguez Islas, Clara P; Brown, Elizabeth R; O'Connell, Sarah E; Montefiori, David C; Eaton, Amanda; Neuzil, Kathleen M; Stephens, David S; Beigel, John H; Pasetti, Marcela; Roberts, Paul C
BACKGROUND:Mucosal immunity plays a critical role in preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and replication. Understanding the capacity of coronavirus disease 2019 (COVID-19) vaccines to elicit both mucosal and systemic antibodies could help optimize vaccination strategies. METHODS:We conducted an open-label, phase 1/2 adaptive-design clinical trial to evaluate the safety and immunogenicity of COVID-19 immunizations. Healthy adults received 2 priming doses of mRNA-1273, a booster dose of mRNA-1273, and a second booster of bivalent (WA-1 and BA.4/BA.5) mRNA-1273.222. Adverse event data were collected. Serum and mucosal immunity were evaluated. RESULTS:One hundred six persons were enrolled. Thirty received all 4 study-related vaccine doses. All vaccines were well tolerated, with injection site pain, malaise, myalgias, and headache being the most frequently reported symptoms. Among those who received a second booster, 24 of 30 (80%) had serological evidence of SARS-CoV-2 infection. Following the second booster, increases in geometric mean binding and pseudovirus neutralization antibody titers to the ancestral strain and BA.1 and BA.5 variants were observed. Increases in mucosal immunoglobulin G and immunoglobulin A (IgA) antibodies in nasal and salivary samples were observed in both previously infected and infection-naive participants, although prior infection markedly boosted virus-specific mucosal IgA responses. CONCLUSIONS:The mRNA-1273.222 booster vaccine was safe and immunogenic and induced mucosal antibody responses in previously infected and infection-naive persons. CLINICAL TRIALS REGISTRATION/BACKGROUND:NCT04889209.
PMID: 40298376
ISSN: 1537-6613
CID: 5833442
The two-dose MVA-BN mpox vaccine induces a nondurable and low avidity MPXV-specific antibody response
Oom, Aaron L; Wilson, Kesi K; Yonatan, Miilani; Rettig, Stephanie; Youn, Heekoung Allison; Tuen, Michael; Shah, Yusra; DuMont, Ashley L; Belli, Hayley M; Zucker, Jane R; Rosen, Jennifer B; Herati, Ramin Sedaghat; Samanovic, Marie I; Duerr, Ralf; Kottkamp, Angelica C; Mulligan, Mark J; ,
UNLABELLED:The 2022 global outbreak of clade IIb mpox was the first major outbreak of mpox outside of African nations. To control the outbreak, public health officials began vaccination campaigns using the third-generation orthopoxvirus vaccine modified vaccinia Ankara from Bavarian Nordic (MVA-BN). Prior to this outbreak, the durability of monkeypox virus (MPXV)-specific immunity induced by MVA-BN was poorly understood. In 2022, we launched the New York City Observational Study of Mpox Immunity (NYC OSMI, NCT05654883), a longitudinal study of 171 participants comprising MVA-BN vaccines and mpox convalescent individuals. Peripheral blood sampling was performed at intervals including prior to vaccination, after one dose, and after the second dose. MVA-BN vaccinees with and without a history of smallpox vaccination demonstrated detectable MPXV-specific memory B cells at 1-year post-vaccination. Additionally, MVA-BN increased MPXV neutralizing titers in smallpox vaccine-naïve vaccinees, with a comparable maximum titer reached in naïve and smallpox vaccine-experienced vaccinees. However, neutralizing titers returned to baseline within 5-7 months for naïve individuals, while remaining elevated in those with prior smallpox vaccination. Both naïve and experienced individuals generated robust IgG responses against MPXV H3 and A35, but naïve vaccinees' IgG responses showed lower avidity than experienced vaccinees. These data highlight a low avidity antibody response elicited by MVA-BN that is short-lived in naïve vaccinees. This work supports the need for long-term studies on protection induced by MVA-BN, including the potential need for booster doses as well as the development of next-generation orthopoxvirus vaccines. IMPORTANCE/OBJECTIVE:The ongoing outbreaks of mpox demonstrate the continuing threat of orthopoxviruses to global health. While previous orthopoxvirus vaccines generated lifelong antibody and cellular immunity, we show here that the current mpox vaccine, MVA-BN or JYNNEOS, fails to induce durable antibody immunity in individuals with no prior smallpox vaccination. This raises the important question of whether MVA-BN vaccinees have long-term protection from mpox. Our work highlights the need for further studies into the durability of protection generated by MVA-BN as well as whether subsequent booster doses are necessary to maintain protection.
PMID: 40162783
ISSN: 1098-5514
CID: 5818712
Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial
Fong, Youyi; Dang, Lauren; Zhang, Bo; Fintzi, Jonathan; Chen, Shiyu; Wang, Jing; Rouphael, Nadine G; Branche, Angela R; Diemert, David J; Falsey, Ann R; Losada, Cecilia; Baden, Lindsey R; Frey, Sharon E; Whitaker, Jennifer A; Little, Susan J; Kamidani, Satoshi; Walter, Emmanuel B; Novak, Richard M; Rupp, Richard; Jackson, Lisa A; Yu, Chenchen; Magaret, Craig A; Molitor, Cindy; Borate, Bhavesh; Babu, Tara M; Kottkamp, Angelica C; Luetkemeyer, Anne F; Immergluck, Lilly C; Presti, Rachel M; Bäcker, Martín; Winokur, Patricia L; Mahgoub, Siham M; Goepfert, Paul A; Fusco, Dahlene N; Atmar, Robert L; Posavad, Christine M; Mu, Jinjian; Makowski, Mat; Makhene, Mamodikoe K; Nayak, Seema U; Roberts, Paul C; Follmann, Dean; Gilbert, Peter B; ,
For COVAIL recipients of a coronavirus disease 2019 (COVID-19) Sanofi booster vaccine, neutralizing antibody titers were assessed as a correlate of risk (CoR) of COVID-19. Peak and exposure-proximal titers were inverse CoRs with covariate-adjusted hazard ratios (95% confidence intervals) 0.30 (0.11, 0.78) and 0.25 (0.07, 0.85) per 10-fold increase in weighted average titer.
PMCID:11797383
PMID: 39325506
ISSN: 1537-6591
CID: 5783432
Neutralizing antibody immune correlates in COVAIL trial recipients of an mRNA second COVID-19 vaccine boost
Zhang, Bo; Fong, Youyi; Dang, Lauren; Fintzi, Jonathan; Chen, Shiyu; Wang, Jing; Rouphael, Nadine G; Branche, Angela R; Diemert, David J; Falsey, Ann R; Graciaa, Daniel S; Baden, Lindsey R; Frey, Sharon E; Whitaker, Jennifer A; Little, Susan J; Kamidani, Satoshi; Walter, Emmanuel B; Novak, Richard M; Rupp, Richard; Jackson, Lisa A; Yu, Chenchen; Magaret, Craig A; Molitor, Cindy; Borate, Bhavesh; Busch, Sydney; Benkeser, David; Netzl, Antonia; Smith, Derek J; Babu, Tara M; Kottkamp, Angelica C; Luetkemeyer, Anne F; Immergluck, Lilly C; Presti, Rachel M; Bäcker, Martín; Winokur, Patricia L; Mahgoub, Siham M; Goepfert, Paul A; Fusco, Dahlene N; Atmar, Robert L; Posavad, Christine M; Mu, Jinjian; Makowski, Mat; Makhene, Mamodikoe K; Nayak, Seema U; Roberts, Paul C; Gilbert, Peter B; Follmann, Dean; ,
Neutralizing antibody titer has been a surrogate endpoint for guiding COVID-19 vaccine approval and use, although the pandemic's evolution and the introduction of variant-adapted vaccine boosters raise questions as to this surrogate's contemporary performance. For 985 recipients of an mRNA second bivalent or monovalent booster containing various Spike inserts [Prototype (Ancestral), Beta, Delta, and/or Omicron BA.1 or BA.4/5] in the COVAIL trial (NCT05289037), titers against 5 strains were assessed as correlates of risk of symptomatic COVID-19 ("COVID-19") and as correlates of relative (Pfizer-BioNTech Omicron vs. Prototype) booster protection against COVID-19 over 6 months of follow-up during the BA.2-BA.5 Omicron-dominant period. Consistently across the Moderna and Pfizer-BioNTech vaccine platforms and across all variant Spike inserts assessed, both peak and exposure-proximal ("predicted-at-exposure") titers correlated with lower Omicron COVID-19 risk in individuals previously infected with SARS-CoV-2, albeit significantly less so in naïve individuals [e.g., exposure-proximal hazard ratio per 10-fold increase in BA.1 titer 0.74 (95% CI 0.59, 0.94) for naïve vs. 0.41 (95% CI 0.23, 0.64) for non-naïve; interaction p = 0.013]. Neutralizing antibody titer was a strong inverse correlate of Omicron COVID-19 in non-naïve individuals and a weaker correlate in naïve individuals, posing questions about how prior infection alters the neutralization correlate.
PMCID:11748719
PMID: 39824819
ISSN: 2041-1723
CID: 5777762
Immunogenicity of a Two Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical Trial
Rouphael, Nadine G; Branche, Angela R; Diemert, David J; Falsey, Ann R; Losada, Cecilia; Baden, Lindsey R; Frey, Sharon E; Whitaker, Jennifer A; Little, Susan J; Kamidani, Satoshi; Walter, Emmanuel B; Novak, Richard M; Rupp, Richard; Jackson, Lisa A; Babu, Tara M; Kottkamp, Angelica C; Luetkemeyer, Anne F; Immergluck, Lilly C; Presti, Rachel M; Bäcker, MartÃn; Winokur, Patricia L; Mahgoub, Siham M; Goepfert, Paul A; Fusco, Dahlene N; Atmar, Robert L; Posavad, Christine M; Netzl, Antonia; Smith, Derek J; Telu, Kalyani; Mu, Jinjian; McQuarrie, Lisa J; Makowski, Mat; Makhene, Mamodikoe K; Crandon, Sonja; Montefiori, David C; Roberts, Paul C; Beigel, John H
We compared the serologic responses of one versus two doses of a variant vaccine (Moderna mRNA-1273 Beta/Omicron BA.1 bivalent vaccine) in adults. A two-dose boosting regimen with a variant vaccine did not increase the magnitude or the durability of the serological responses compared to a single variant vaccine boost.
PMID: 37561027
ISSN: 1537-6613
CID: 5605532
Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial
Branche, Angela R; Rouphael, Nadine G; Diemert, David J; Falsey, Ann R; Losada, Cecilia; Baden, Lindsey R; Frey, Sharon E; Whitaker, Jennifer A; Little, Susan J; Anderson, Evan J; Walter, Emmanuel B; Novak, Richard M; Rupp, Richard; Jackson, Lisa A; Babu, Tara M; Kottkamp, Angelica C; Luetkemeyer, Anne F; Immergluck, Lilly C; Presti, Rachel M; Bäcker, MartÃn; Winokur, Patricia L; Mahgoub, Siham M; Goepfert, Paul A; Fusco, Dahlene N; Malkin, Elissa; Bethony, Jeffrey M; Walsh, Edward E; Graciaa, Daniel S; Samaha, Hady; Sherman, Amy C; Walsh, Stephen R; Abate, Getahun; Oikonomopoulou, Zacharoula; El Sahly, Hana M; Martin, Thomas C S; Kamidani, Satoshi; Smith, Michael J; Ladner, Benjamin G; Porterfield, Laura; Dunstan, Maya; Wald, Anna; Davis, Tamia; Atmar, Robert L; Mulligan, Mark J; Lyke, Kirsten E; Posavad, Christine M; Meagher, Megan A; Stephens, David S; Neuzil, Kathleen M; Abebe, Kuleni; Hill, Heather; Albert, Jim; Telu, Kalyani; Mu, Jinjian; Lewis, Teri C; Giebeig, Lisa A; Eaton, Amanda; Netzl, Antonia; Wilks, Samuel H; Türeli, Sina; Makhene, Mamodikoe; Crandon, Sonja; Montefiori, David C; Makowski, Mat; Smith, Derek J; Nayak, Seema U; Roberts, Paul C; Beigel, John H; ,
Vaccine protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection wanes over time, requiring updated boosters. In a phase 2, open-label, randomized clinical trial with sequentially enrolled stages at 22 US sites, we assessed safety and immunogenicity of a second boost with monovalent or bivalent variant vaccines from mRNA and protein-based platforms targeting wild-type, Beta, Delta and Omicron BA.1 spike antigens. The primary outcome was pseudovirus neutralization titers at 50% inhibitory dilution (ID50 titers) with 95% confidence intervals against different SARS-CoV-2 strains. The secondary outcome assessed safety by solicited local and systemic adverse events (AEs), unsolicited AEs, serious AEs and AEs of special interest. Boosting with prototype/wild-type vaccines produced numerically lower ID50 titers than any variant-containing vaccine against all variants. Conversely, boosting with a variant vaccine excluding prototype was not associated with decreased neutralization against D614G. Omicron BA.1 or Beta monovalent vaccines were nearly equivalent to Omicron BA.1 + prototype or Beta + prototype bivalent vaccines for neutralization of Beta, Omicron BA.1 and Omicron BA.4/5, although they were lower for contemporaneous Omicron subvariants. Safety was similar across arms and stages and comparable to previous reports. Our study shows that updated vaccines targeting Beta or Omicron BA.1 provide broadly crossprotective neutralizing antibody responses against diverse SARS-CoV-2 variants without sacrificing immunity to the ancestral strain. ClinicalTrials.gov registration: NCT05289037 .
PMID: 37640860
ISSN: 1546-170x
CID: 5605562